UBS Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-45,436
| Closed | -$72.2K | – | 9089 |
|
|
2024
Q1 | $72.2K | Sell |
45,436
-1,368
| -3% | -$2.18K | ﹤0.01% | 5194 |
|
|
2023
Q4 | $40.2K | Buy |
46,804
+24,624
| +111% | +$21.2K | ﹤0.01% | 5466 |
|
|
2023
Q3 | $23.7K | Buy |
+22,180
| New | +$23.7K | ﹤0.01% | 5579 |
|
|
2023
Q2 | – | Sell |
-2,896
| Closed | -$11.8K | – | 8725 |
|
|
2023
Q1 | $11.8K | Sell |
2,896
-1,835
| -39% | -$7.49K | ﹤0.01% | 6383 |
|
|
2022
Q4 | $23.8K | Buy |
+4,731
| New | +$23.8K | ﹤0.01% | 6300 |
|
|
2022
Q1 | – | Sell |
-2,673
| Closed | -$47K | – | 9818 |
|
|
2021
Q4 | $47K | Buy |
2,673
+1,866
| +231% | +$32.8K | ﹤0.01% | 5876 |
|
|
2021
Q3 | $17K | Sell |
807
-4,140
| -84% | -$87.2K | ﹤0.01% | 6226 |
|
|
2021
Q2 | $98K | Sell |
4,947
-37,253
| -88% | -$738K | ﹤0.01% | 4859 |
|
|
2021
Q1 | $1.23M | Buy |
42,200
+23,900
| +131% | +$694K | ﹤0.01% | 3181 |
|
|
2020
Q4 | $554K | Buy |
18,300
+6,000
| +49% | +$182K | ﹤0.01% | 3609 |
|
|
2020
Q3 | $196K | Buy |
12,300
+2,711
| +28% | +$43.2K | ﹤0.01% | 3994 |
|
|
2020
Q2 | $189K | Sell |
9,589
-945
| -9% | -$18.6K | ﹤0.01% | 4044 |
|
|
2020
Q1 | $130K | Sell |
10,534
-16,125
| -60% | -$199K | ﹤0.01% | 4211 |
|
|
2019
Q4 | $492K | Buy |
26,659
+17,542
| +192% | +$324K | ﹤0.01% | 3907 |
|
|
2019
Q3 | $127K | Buy |
9,117
+7,904
| +652% | +$110K | ﹤0.01% | 4696 |
|
|
2019
Q2 | $18K | Buy |
+1,213
| New | +$18K | ﹤0.01% | 5823 |
|